TrovaGene Inc (NASDAQ: TROV) is having a great start to the trading session this morning, trading up more than 18% after announcing positive preclinical data further validating its work with Onvansertib. TrovaGene is a company that I’ve followed closely. If you’re unfamiliar with their work, consider reading my full report here.
Nonetheless, the data that was released today not only helps to validate the work that the company is doing with Onvansertib, it serves to validate my bullish opinion on the stock. Let’s dive in:
TROV Announces Positive Onvansertib Data
In a press release issued this morning, TrovaGene issued a clinical update, sharing preclinical data surrounding its lead clinical candidate, Onvansertib. Currently, Onvansertib is in the midst of a Phase 1b/2 clinical trial (we’ll talk about that in a moment).
Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!
In the release, TROV announced preclinical data that evaluated the effect of combining onvansertib with venetoclax. The combination was introduced to an AML cell model that is known to be resistant to venetoclax.
Nonetheless, the combination proved to work around this resistance. In fact, the data showed a significant decrease in tumor cell viability.
Why This Data Is Important
As mentioned above, Onvansertib is currently in the midst of a Phase 1b/2 clinical trial in patients with relapsed/refractory AML. At the moment, there are limited treatment options for this condition, creating an incredibly high clinical need for new options.
The data that was released today further supports the company’s work in this trial. Through the trial, the company is providing patients with a combination of Onvansertib and standard-of-care chemotherapy.
So far, data in the clinical trial has been encouraging. For more details on the data, click the link at the top of this article to read my detailed report on Trovagene. Nonetheless, we have seen strong safety and preliminary efficacy data from the treatment.
With today’s data showing a strong synergy in combination with venetoclax shows yet again that Onvansertib, when combined with chemotherapy, could prove to be an effective, and much needed treatment option for this patient population. So, with the preclinical data that was released today, the ongoing trial has some serious promise of producing positive top-line results.
In a statement, Dr. Mark Erlander, Chief Scientific Officer at TROV, had the following to offer:
We investigated the combination of onvansertib and venetoclax in a cell model, with known resistance to venetoclax, given that venetoclax as a single agent had previously shown a relatively low response rate of approximately 19% in relapsed/refractory AML.
Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!
We believe the positive results of our preclinical study provides the scientific rationale for clinical investigation of this combination regimen and may lead to a new treatment option for these patients.
Final Thoughts
Since I started following TrovaGene late last year, the company has issued several positive press releases, showing strong progress in the advancement of Onvansertib through the development process. As the treatment continues to lead to positive results, the promise of this being a viable option for a difficult-to-treat patient population only grows.
Considering the vast market potential that relapsed/refractory AML comes with, along with the company’s work in the metastatic castration resistant prostate cancer indication makes TROV a stock that is hard not to pay attention to!